GYRE THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GYRE THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $127.0K | Mar 16, 2015 |
| FY2014 | Sep 30, 2014 | $25.0K | Mar 16, 2015 |
| FY2014 | Jun 30, 2014 | $36.0K | Mar 16, 2015 |
| FY2014 | Mar 31, 2014 | $87.0K | Mar 16, 2015 |
| FY2014 | Dec 31, 2013 | $93.0K | Mar 16, 2015 |
| FY2014 | Mar 31, 2013 | $3.54M | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | $590.0K | Mar 14, 2014 |
| FY2013 | Sep 30, 2012 | $768.0K | Mar 14, 2014 |
| FY2013 | Jun 30, 2012 | $33.65M | Mar 14, 2014 |
| FY2013 | Mar 31, 2012 | $22.86M | Mar 14, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.59M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $105.76M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $113.45M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $102.29M | Mar 27, 2024 |
| FY2021 | Dec 31, 2021 | $7.34M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $20.95M | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $6.0K | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $1.02M | Mar 8, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $101.87M | Mar 17, 2025 |
| FY2024 | Dec 31, 2023 | $108.81M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $97.50M | Mar 27, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.88M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $17.90M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($85.48M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $4.31M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($87.93M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($56.24M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($55.18M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($30.06M) | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | ($21.56M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($16.95M) | Mar 19, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.49M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $16.16M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($67.23M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $9.20M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($87.89M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($57.37M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($57.28M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($33.82M) | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | ($21.82M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($20.42M) | Mar 19, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.70M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $12.02M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $13.78M | Mar 17, 2025 |
| FY2021 | Dec 31, 2021 | $68.89M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $52.98M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $43.86M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $21.47M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $12.85M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $11.56M | Mar 19, 2018 |
| FY2016 | Dec 31, 2015 | $5.96M | Mar 8, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.01M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($3.64M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $25.89M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $10.68M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($83.76M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($55.05M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($43.61M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($28.55M) | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | ($19.94M) | Mar 8, 2019 |
| FY2013 | Dec 31, 2013 | ($40.61M) | Mar 14, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.19M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.32M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $8.52M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $4.99M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $839.0K | Mar 30, 2023 |
| FY2019 | Dec 31, 2019 | $64.0K | Feb 20, 2020 |
| FY2019 | Dec 31, 2018 | $376.0K | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $23.0K | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $468.0K | Mar 19, 2018 |
| FY2016 | Dec 31, 2015 | $272.0K | Mar 8, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.13M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $125.41M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $116.54M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $84.75M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $55.66M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $94.85M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $98.55M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $124.92M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $39.51M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $38.09M | Mar 19, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.85M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $27.00M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $38.07M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $12.54M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $14.57M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $18.78M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $30.22M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $4.98M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $8.74M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $22.02M | Mar 19, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.03M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $63.32M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($15.83M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $42.52M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $41.09M | Mar 30, 2023 |
| FY2022 | Dec 31, 2020 | $76.07M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $68.34M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $119.95M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $30.77M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $16.07M | Mar 8, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($68.43M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($73.45M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($85.54M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $7.40M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($402.69M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($314.76M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($258.52M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($203.34M) | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | ($173.49M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($147.98M) | Mar 19, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.07M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $11.81M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $33.51M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $25.18M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $44.35M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $30.36M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $15.37M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $31.21M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $14.47M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $10.26M | Mar 19, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $0 | Mar 16, 2015 |
| FY2013 | Dec 31, 2013 | $1.14M | Mar 14, 2014 |
| FY2012 | Dec 31, 2012 | $1.99M | Mar 15, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
| FY2014 | Dec 31, 2014 | 0 | Mar 16, 2015 |
| FY2014 | Sep 30, 2014 | 0 | Mar 16, 2015 |
| FY2014 | Jun 30, 2014 | 0 | Mar 16, 2015 |
| FY2014 | Mar 31, 2014 | 0 | Mar 16, 2015 |
| FY2014 | Dec 31, 2013 | 0 | Mar 16, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
| FY2013 | Dec 31, 2012 | 0 | Mar 14, 2014 |
| FY2013 | Sep 30, 2012 | 0 | Mar 14, 2014 |
| FY2013 | Jun 30, 2012 | 0 | Mar 14, 2014 |
| FY2013 | Mar 31, 2012 | 0 | Mar 14, 2014 |
| FY2012 | Dec 31, 2011 | 0 | Mar 15, 2013 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 91.31M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 86.31M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 76.60M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 63.59M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 31.41M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 22.10M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 12.04M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | 11.95M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | 6.08M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | 801,756 | Mar 19, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 27, 2022 | $7.60M | Mar 30, 2023 |
| FY2022 | Sep 20, 2022 | $45.00M | Mar 30, 2023 |